NAD Finds Health-Related Claims for Pendulum Glucose Control Medical Probiotic Supported but Recommends Some Modifications
Contact: Abby Hills, Director of Communications, BBB National Programs
703.247.9330 / firstname.lastname@example.org
- “The only medical probiotic clinically shown to lower A1C & blood glucose spikes for the dietary management of T2D* (*Consult your physician as part of your total diabetes management plan. Results may vary from person to person)”; and
- “The only probiotic clinically shown to lower glucose spikes by 33% and reduce A1C levels by 0.6 in people with type 2 diabetes.”
However, NAD recommended the following modifications so that the claims more accurately reflect the limitations in the evidence by:
- Limiting the claims to individuals who are taking metformin;
- Modifying the claims to clarify that the product can be used as part of the dietary management of type 2 diabetes; and
- Removing references to percent reductions in blood glucose spikes in the absence of evidence in the record demonstrating that the reductions were clinically relevant.
The claims at issue were challenged as part of NAD’s routine monitoring program. During the pendency of the case, the advertiser voluntarily modified many of the challenged claims permanently, therefore, NAD did not review these claims on the merits.
In support of its claims, the advertiser chiefly relied on the Perraudeau Study assessing Pendulum Glucose Control’s effectiveness in helping Type 2 diabetes dietary management. NAD determined that this study had some appropriate methodological components (double-blind, randomized, placebo-controlled, sufficiently large sample size to elicit statistically significant and clinically meaningful results, testing the marketed product, clearly defined endpoints). However, NAD questioned certain aspects of the study related to test population and clinical relevance of the endpoints.
Based on its assessment, NAD determined that the Perraudeau study was a good fit for the challenged claims but recommended the previously noted modifications.
In its advertiser statement, Pendulum Therapeutics, Inc. stated that it “is pleased with NAD’s decision and will comply with its recommendations.”
All BBB National Programs case decisions can be found in the case decision library.
About BBB National Programs: BBB National Programs is where businesses turn to enhance consumer trust and consumers are heard. The non-profit organization creates a fairer playing field for businesses and a better experience for consumers through the development and delivery of effective third-party accountability and dispute resolution programs. Embracing its role as an independent organization since the restructuring of the Council of Better Business Bureaus in June 2019, BBB National Programs today oversees more than a dozen leading national industry self-regulation programs, and continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-directed marketing, and privacy. To learn more, visit bbbprograms.org.
About the National Advertising Division: The National Advertising Division (NAD), a division of BBB National Programs, provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.
BBB National Programs National Advertising Division Launches Expedited Fast-Track SWIFT Lane Designed to Address Misleading Advertising Disclosures
New York, NY – November 9, 2021 – Mindful of recent Federal Trade Commission (FTC) actions, BBB National Programs today announced a new, streamlined lane of the expedited Fast-Track SWIFT challenge submission process, one designed specifically to address the prominence and sufficiency of...
Media Advisory: FTC Commissioner Rebecca Slaughter to Keynote National Advertising Division “Future of Ad Law” 2021 Annual Conference
New York, NY – September 21, 2021 – In its 50th anniversary year, the National Advertising Division (NAD) of BBB National Programs will host the NAD 2021 Annual Conference virtually next week, running Wednesday, September 29 through Friday, October 1. Members of the media are invited to cover NAD 2021 with...
Children’s Advertising Review Unit Issues Revised Guidelines for Responsible Advertising to Children, Effective January 1, 2022
McLean, VA – July 29, 2021 – BBB National Programs’ Children’s Advertising Review Unit (CARU) today announced the issuance of the revised CARU Advertising Guidelines, widely recognized industry standards to assure that advertising directed to children is not deceptive, unfair, or inappropriate for its intended...
U.S.-Based BBB National Programs Announced as Winner for “Best Sectoral Initiative” by International Council of Advertising Self-Regulation
On 15 June 2021, the International Council for Advertising Self-Regulation (ICAS) announced the winners of its second edition of the ICAS Global Awards. The objective of the ICAS Awards is to reward initiatives that contribute to responsible marketing practices and a more effective and impactful...